EODData

MEMBERSHIP REGISTER LOG IN

FRA, IDD: Innate Pharma S.A

04 Nov 2025
LAST:

1.608

CHANGE:
 0.10		OPEN:
1.608		HIGH:
1.608		ASK:
0.000		VOLUME:
750
CHG(%):
5.74		PREV:
1.706		LOW:
1.608		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
04 Nov 251.6081.6081.6081.608750
31 Oct 251.6681.7061.6681.706750
30 Oct 251.7321.7321.7321.732100
29 Oct 251.6621.6621.6621.662100
28 Oct 251.9061.9061.9061.906100
27 Oct 251.8601.8601.8601.860100
24 Oct 251.8221.8221.8221.822100
23 Oct 251.7781.7921.7781.792100
22 Oct 251.7781.7781.7781.778100
21 Oct 251.7801.7801.7801.780100

COMPANY PROFILE

Name:Innate Pharma S.A
About:Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Sector:Healthcare
Industry:Biotechnology
Address:117, Avenue de Luminy, Marseille, France, 13009
Website:https://www.innate-pharma.com
ISIN:FR0010331421

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-2.64 
Price to Sales:11.73 
Price to Book:28.71 
Operating Margin:-5.23 
Return on Assets:-0.26 
Return on Equity:-2.71 
Revenue:12.64M 
Shares:92.17M 
Market Cap:148.2M 

TECHNICAL INDICATORS

MA5:1.727.1%
MA10:1.769.7%
MA20:1.779.9%
MA50:1.769.4%
MA100:1.726.8%
MA200:1.7911.6%
RSI14:44.27
WPR14:-100.00 
MTM14:-0.05
ROC14:-0.03 
ATR:0.07 
Week High:1.9118.5%
Week Low:1.610.0%
Month High:1.9118.5%
Month Low:1.6111.6%
Year High:2.7268.8%
Year Low:1.3321.2%
Volatility:31.03